« FDA Approvals - Scientific Protein Laboratories LLC Statement Regarding FDA Briefing On Heparin | Main | Palo Alto Labs Issues a Voluntary Nationwide Recall of Aspire36 »

ActivBiotics Receives FDA Orphan Drug Designation For Superoxide Dismutase Mimetic,


ActivBiotics Receives FDA Orphan Drug Designation For Superoxide Dismutase Mimetic, M40403, In Oral Mucositis Of Cancer (Medical News Today)
Joseph F. Finn, Jr., CPA, the Assignee for the Benefit of Creditors of ActivBiotics, announced that the Office of Orphan Products Development of the Food and Drug Administration (FDA) has granted Orphan Drug Designation for M40403 for the prevention of radiation -- or chemotherapy -- induced oral mucositis (OM) in cancer patients.
 

©2006 FDA-News.com. All rights reserved.